cardiovascular gene therapy (VIB)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namecardiovascular gene therapy (VIB)
Drug Alias Namecardiovascular gene therapy (IntroGene)eNOS gene therapy (Crucell)cardiovascular gene therapy (Crucell)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy
Mechanisms of ActionFibrinolysis modulatorsNitric oxide synthesis modulatorsPlasminogen activators modulators
TargetsPlasminogen activators
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVlaams Instituut voor Biotechnologie
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrucell NVVlaams Instituut voor Biotechnologie
Active IndicationsN/A
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A